Skip to main content

Advertisement

SpringerLink
Log in

Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Breast cancer is the most common invasive type of cancer among women. Role of different microRNAs (miRNAs) and poly(ADP-ribose) polymerases (PARPs) in breast cancer has been well established. This study aimed to explore the effects of miR-891b on sensitizing breast cancer cells to alkylating chemotherapeutic drugs through PARPs.

Methods

The expression of miR-891b and PARP1 in human breast cancer cells HCC1806 was overexpressed by transfection with their mimics or expressing vector. Then, the transfected cells were exposed to 40 µM N-methyl-N-nitro-N-nitrosoguanidine (MNNG) for 1 h. The correlation between miR-891b and PARP1 was detected by RT-qPCR, western blot, and dual-luciferase reporter assay. Besides, MTT assay and Annexin V assay were done to measure cell proliferation and apoptosis, respectively.

Results

PARP1 was a target of miR-891b, and it was negatively regulated by miR-891b. MiR-891b increased the sensitivity of the HCC1806 cells to the cytotoxic effects of MNNG through suppressing cell proliferation and increasing the percentage of apoptotic cells. Restoration of PARP1 activity in the HCC1806 cells led to loss of miR-891b mediated sensitivity of the HCC1806 cells to MNNG.

Conclusion

MiR-891b increases the sensitivity of the breast cancer cells (HCC1806) to the cytotoxic effects of the chemotherapeutic agent MNNG by suppressing the expression of PARP1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. McGuire A et al (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7(2):908–929

    Article  Google Scholar 

  2. McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7(2):418–419

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cardoso F et al (2017) Research needs in breast cancer. Ann Oncol 28:208–217

    CAS  PubMed  Google Scholar 

  4. Mustafa M et al (2013) Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 6:CD004253

    Google Scholar 

  5. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22

    Article  CAS  PubMed  Google Scholar 

  6. Kim JS et al (2014) MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Mol Cell Biochem 387(1–2):71–79

    Article  CAS  PubMed  Google Scholar 

  7. Diab M et al (2016) The role of microRNAs in the diagnosis and treatment of pancreatic adenocarcinoma. J Clin Med 5(6):59

    Article  PubMed Central  Google Scholar 

  8. Zhang B et al (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12

    Article  CAS  PubMed  Google Scholar 

  9. Meltzer PS (2005) Cancer genomics: small RNAs with big impacts. Nature 435(7043):745–746

    Article  CAS  PubMed  Google Scholar 

  10. Riaz M et al (2013) miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 15(2):R33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rouleau M et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293–301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shi Wei et al (2016) MiR-449a promotes breast cancer progression by targeting CRIP2. Oncotarget 7(14):18906–18918

    Article  PubMed  PubMed Central  Google Scholar 

  14. Fang H et al (2017) miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res 9(3):953

    PubMed  PubMed Central  Google Scholar 

  15. He J et al (2017) miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2. Oncol Rep 37(5):2672–2678

    PubMed  PubMed Central  Google Scholar 

  16. Rodriguez-Barrueco R et al (2017) miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev 31(6):553–566

    Article  CAS  PubMed  Google Scholar 

  17. Zhao G, Li Y, Wang T (2017) Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun 487:255–261

    Article  CAS  PubMed  Google Scholar 

  18. Fan X et al (2017) MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother 88:507

    Article  CAS  PubMed  Google Scholar 

  19. Hakme A et al (2008) The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: beyond the Usual Suspects’ Review Series. EMBO Rep 9(11):1094–1100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Schreiber V et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7(7):517–528

    Article  CAS  PubMed  Google Scholar 

  21. Megnin-Chanet F, Bollet MA, Hall J (2010) Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci 67(21):3649–3662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5(4):387–393

    Article  CAS  PubMed  Google Scholar 

  23. Murai J et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Belleannee C et al (2012) Role of microRNAs in controlling gene expression in different segments of the human epididymis. PLoS One 7(4):e34996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dong Q et al (2016) MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget 7(50):82338–82353

    PubMed  PubMed Central  Google Scholar 

  26. Durkacz BW et al (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283(5747):593–596

    Article  CAS  PubMed  Google Scholar 

  27. Banasik M et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267(3):1569–1575

    CAS  PubMed  Google Scholar 

  28. AlHilli MM et al (2016) In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol 143(2):379–388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rugo HS et al (2016) Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Munroe M, Kolesar J (2016) Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm 73(14):1037–1041

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China

    Shujian Xu

  2. Department of Thyroid and Breast Surgery, The Affiliated Hospital to Binzhou Medical University, No. 661, Huangheer Road, Bincheng District, Binzhou, 256603, China

    Shujian Xu, Zhongming Jia, Xilong Wang, Yong Han & Zhenlin Yang

  3. Department of Rehabilitation Medicine, The Affiliated Hospital to Binzhou Medical University, Binzhou, 256603, China

    Cui Zhao

Authors
  1. Shujian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cui Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhongming Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xilong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhenlin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SJX: protocol development, data collection, data analysis, and manuscript writing. CZ: protocol development, data collection, and data analysis. ZMJ: data collection and data analysis. XLW: data collection and data analysis. YH: data collection and data analysis. ZLY: protocol development and manuscript editing.

Corresponding author

Correspondence to Zhenlin Yang.

Ethics declarations

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors of this study declare no conflicts of interest in this work.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, S., Zhao, C., Jia, Z. et al. Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs. Arch Gynecol Obstet 296, 543–549 (2017). https://doi.org/10.1007/s00404-017-4444-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-017-4444-3

Keywords

Search

Navigation